UK-specific cost-effectiveness of tiotropium + olodaterol fixed-dose combination versus other LAMA + LABA combinations in patients with COPD

OBJECTIVE: The aim of this study is to assess the cost-effectiveness of other long-acting muscarinic antagonist + long-acting β2 agonist combinations in comparison with Spiolto(®) Respimat(®) (tiotropium + olodaterol fixed-dose combination [FDC]) for maintenance treatment to relieve symptoms in adul...

Descripción completa

Detalles Bibliográficos
Autores principales: Tebboth, Abigail, Ternouth, Andrew, Gonzalez-Rojas, Nuria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5106216/
https://www.ncbi.nlm.nih.gov/pubmed/27853383
http://dx.doi.org/10.2147/CEOR.S116546

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5106216/
https://www.ncbi.nlm.nih.gov/pubmed/27853383
http://dx.doi.org/10.2147/CEOR.S116546

Ejemplares similares